Zileutonum [INN-Latin] en es it fr

Zileutonum [INN-Latin] Brand names, Zileutonum [INN-Latin] Analogs

Zileutonum [INN-Latin] Brand Names Mixture

  • No information avaliable

Zileutonum [INN-Latin] Chemical_Formula


Zileutonum [INN-Latin] RX_link


Zileutonum [INN-Latin] fda sheet

Zileutonum [INN-Latin] msds (material safety sheet)

Zileutonum_[INN-Latin] MSDS

Zileutonum [INN-Latin] Synthesis Reference

No information avaliable

Zileutonum [INN-Latin] Molecular Weight

236.291 g/mol

Zileutonum [INN-Latin] Melting Point

144.2-145.2 oC

Zileutonum [INN-Latin] H2O Solubility

Practically insoluble (0.5 mg/ml)

Zileutonum [INN-Latin] State


Zileutonum [INN-Latin] LogP


Zileutonum [INN-Latin] Dosage Forms

Tablet (600mg)

Zileutonum [INN-Latin] Indication

For the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.

Zileutonum [INN-Latin] Pharmacology

Zileuton is an asthma drug. It blocks leukotriene synthesis by inhibiting 5-lipoxygenase, an enzyme of the eicosanoid synthesis pathway. Sulfido-peptide leukotrienes (LTC4, LTD4, LTE4, also known as the slow-releasing substances of anaphylaxis) and LTB4, a chemoattractant for neutrophils and eosinophils, can be measured in a number of biological fluids including bronchoalveolar lavage fluid (BALF) from asthmatic patients. In humans, pretreatment with zileuton attenuated bronchoconstriction caused by cold air challenge in patients with asthma.

Zileutonum [INN-Latin] Absorption

Rapidly and almost completely absorbed. The absolute bioavailability is unknown.

Zileutonum [INN-Latin] side effects and Toxicity

The oral minimum lethal doses in mice and rats were 500-4000 and 300-1000 mg/kg in various preparations, respectively (providing greater than 3 and 9 times the systemic exposure [AUC] achieved at the maximum recommended human daily oral dose, respectively).

Zileutonum [INN-Latin] Patient Information

Patients should be told that:

  • ZYFLO is indicated for the chronic treatment of asthma and should be taken regularly as prescribed, even during symptom-free periods.
  • ZYFLO is not a bronchodilator and should not be used to treat acute episodes of asthma.
  • When taking ZYFLO, they should not decrease the dose or stop taking any other antiasthma medications unless instructed by a physician.
  • While using ZYFLO, medical attention should be sought if short-acting bronchodilators are needed more often than usual, or if more than the maximum number of inhalations of short-acting bronchodilator treatment prescribed for a 24-hour period are needed.
  • The most serious side effect of ZYFLO is elevation of liver enzyme tests and that, while taking ZYFLO, they must return for liver enzyme test monitoring on a regular basis. If they experience signs and/or symptoms of liver dysfunction (e.g., right upper quadrant pain, nausea, fatigue, lethargy, pruritus, jaundice, or "flu-like" symptoms), they should contact their physician immediately.
  • ZYFLO can interact with other drugs and that, while taking ZYFLO, they should consult their doctor before starting or stopping any prescription or non-prescription medicines.

A patient leaflet is included with the tablets.

Zileutonum [INN-Latin] Organisms Affected

Humans and other mammals